Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

Appili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501, a liquid oral formulation of the antibiotic metronidazole. HALIFAX, Nova Scotia — Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused […]